Results of a Dutch cost-effectiveness model of radium-223 in comparison to cabazitaxel, abiraterone, and enzalutamide in patients with metastatic castration resistant prostate cancer previously treated with docetaxel

JG Gaultney, A Baka, A Leliveld-Kors, W Noordzij, D Wyndaele, C de Meijer

OnderzoeksoutputAcademic

Originele taal-2English
StatusPublished - nov.-2015

Citeer dit